Mosaic Mitral Bioprosthesis

The Mosaic™ mitral bioprosthesis allows leaflets to remain soft and flexible, which protects the tissue from cyclic fatigue.

Overview

Built for a life. Time tested.

The Mosaic mitral bioprosthesis — based on more than 50 years of Medtronic tissue-valve design expertise — is a great option for surgeons seeking unsurpassed long-term durability, excellent hemodynamics, and a smooth implanting experience.

Lifetime patient management wheel visual for Mosaic bioprosthesis

Product features

Durability

Published clinical experience demonstrates industry-leading long-term performance. 

Features that may contribute to durability are:

  • Proprietary AOA™ anti-calcification tissue treatment with clinical use in more than half a million patients for over 30 years.
  • High-performance stent that allows for absorption of stress produced during the cardiac cycle.
  • Physiologic fixation, our advanced tissue fixation process, to mitigate biomechanical failures and promote long-term valve durability by: 
    • Improving preservation of valve structure and leaflet function, allowing it to function similar to a native valve.
    • Allowing leaflets to remain soft and flexible, which protects the tissue from cyclic fatigue.

Watch the video to learn more about Mosaic mitral's unsurpassed durability.

pdf Download brochure (.pdf)

Discover how Epic™* valves compare to Mosaic mitral valve.

2.1MB

pdf Download brochure (.pdf)

See how Edwards™* Lifesciences valves compare to Mosaic mitral valve.

1.2MB

AOA anti-calcification treatment

The Medtronic-patented AOA tissue treatment mitigates calcification and protects the tissue.

  • AOA covalently bonds with free aldehydes and washes lipids away.
  • Large AOA molecules slow diffusion of calcium into tissue matrix.

Physiologic tissue fixation

  1. Leaflets float at net-zero pressure.
  2. Roots are pressurized at 40 mmHg with glutaraldehyde.
Valve tissue fixation design illustration

Long-term outcomes of mitral valve replacements

Mosaic mitral versus Perimount™*
This retrospective, single-center study compared the long-term outcomes of Mosaic porcine mitral valves to Carpentier-Edwards bovine pericardial mitral valves in 940 patients.1

Cumulative incidence of reoperation at 15 years (p < 0.001):

  • 7.9% for Mosaic mitral
  • 13.2% for CE Perimount or Magna mitral


On average, the time before reoperation for SVD was 4.3 years longer with Mosaic porcine valves than Edwards pericardial valves.

See more

Time to reoperation for SVD

Blue and pink bar chart comparing Mosaic to the Edwards pericardial valve in time to reoperation for SVD

Hemodynamics

The Mosaic mitral bioprosthesis was designed to allow for maximum blood flow. The creation of the valve — from the porcine leaflets and valve geometry (specifically stent height) to how the tissue is mounted in the frame — affects how optimally the blood flows in diastole, and how well the leaflets coapt in systole.

As reported in the Mosaic mitral bioprosthesis instructions for use, hemodynamic results at one year2:

Mosaic mitral size3

25

27

29

31

33

Mean gradient (mm) (n = )

5.7 ± 1.7 (41)

4.6 ± 2.1 (98)

4.4 ± 1.8 (123)

3.7 ± 1.4 (50)

3.4 ± 1.8 (8)

Mean EOA (cm2) (n =)

1.6 ± 0.4 (35)

1.7 ± 0.5 (90)

1.8 ± 0.5 (114)

1.7 ± 0.5 (43)

1.9 ± 0.5 (6)

Geometry and reintervention

Designed to accommodate ventricular flow

The Mosaic mitral valve reflects the asymmetry of the native porcine valve. The largest leaflet of the Mosaic mitral bioprosthesis is intended to align with the patient’s anterior mitral leaflet to accommodate ventricular flow.

Native design offers one wider leaflet.

The asymmetrical design of Mosaic offers one wider leaflet spaced at 135° with an interstrut distance of 18.4 mm in size 29, for example.

Illustration of asymmetrical design of Mosaic bioprosthesis shown from the top, side, and within the heart

Suitable for future interventions

Valve dimensions and geometry facilitate future valve-in-valve (ViV) procedures.

  • Radiopaque stent post eyelets on the Mosaic mitral valve provide visible markers to help correctly position the transcatheter valve during ViV procedures.
  • MR Conditional, nonmetallic frame mitigates risk of corrosion between surgical valve and transcatheter valve stent materials.
Radiopaque Sapien device deployed inside the Mosaic mitral bioprosthesis

Sapien™* device deployed inside Mosaic mitral

Implantability

The Cinch™ implant system capitalizes on the flexible stent to facilitate valve implantation, particularly through tight patient anatomy:

  • Aids minimally invasive procedures
  • Helps prevent suture looping
  • Protects tissue from inadvertent damage and prevents entanglement with the sub-valvular apparatus
  • Assists implantation with clear markings for proper orientation
  • Offers smooth needle penetration and suture placement with a fluffy, conformable cuff
  • Provides improved visibility for proper implant orientation, which may reduce the risk of complications
Cinch implant system attached Mosaic bioprosthesis showing open and shut

Ordering information

Mosaic mitral valve, Model 310

Order
number

Valve size
(stent O.D.
)
(± 0.5 mm)

Orifice
diameter
(stent I.D.)
(± 0.5 mm)

Suture ring
diameter
(± 1 mm)

Valve height
(± 0.5 mm)

Ventricular
protrusion
(± 0.5 mm)

 

(A)

(B)

(C)

(D)

(E)

310C25

25

22.5

33.0

18.0

13.5

310C27

27

24.0

35.0

19.0

14.0

310C29

29

26.0

38.0

20.5

15.5

310C31

31

28.0

41.0

22.0

17.0

310C33

33

30.0

43.0

23.0

17.5

Outlined illustration of Mosaic mitral valve model 310 with sizing callouts on white background

Accessories

Order number

Description

T7615MSM

Tray, accessory, Mosaic mitral

7639

Handle (234 mm length) pliant, without locknut to be used with Mosaic or Mosaic Ultra prostheses

7639XL

Handle (368 mm length) pliant, without locknut to be used with Mosaic or Mosaic Ultra prostheses

7310

Mosaic mitral obturator set (no handles, no tray)

*

™Third-party brands are trademarks of their respective owners.

The benefits of AOA™ tissue treatment have been demonstrated through animal testing. No direct clinical evaluation of the benefits of AOA™ treatment in humans has been conducted.

Equivalent to annulus diameter.

References

1

Beute T, Goehler M, Parker J, et al. Long-term outcomes of Mosaic versus Perimount mitral replacements: 17-year follow up of 940 implants. Ann Thorac Surg. 2020;110(2):508–515.

2

Mosaic porcine bioprosthesis instructions for use. Medtronic, Inc. 1220016001 Rev. 1C; 2018.

3

Rieß FC, Fradet G, Lavoie A, Legget M. Long-term outcomes of Mosaic bioprosthesis. Ann Thorac Surg. 2018;105(3):763–769.

4

Data on file at Medtronic. Report #D00807486_A, July 28, 2022.